+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

I

Actively Recruiting

Researchers are evaluating the use of intravenous tenecteplase for treating acute ischemic stroke when the exact time of stroke onset is unknown, such as in wake-up stroke cases. This phase 3, multicenter, randomized trial aims to determine the safety and effectiveness of tenecteplase compared to standard medical treatment using non-contrast CT for patient selection. The main goal is to assess excellent patient outcomes based on functional status 90 days after treatment. Participants will be randomly assigned to one of two groups one group receives intravenous tenecteplase at a dose of 0.25 mgkg up to 25 mg plus standard medical care, and the other group receives standard medical care alone without thrombolysis. Tenecteplase is given as a single intravenous bolus soon after randomization. Standard medical treatment includes therapies such as antiplatelets, anticoagulants, blood pressure, and cholesterol management according to local guidelines. During the study, participants will be monitored and evaluated with assessments including neurological scales, disability scores, and quality of life questionnaires at various time points up to 90 days. The primary measure is an excellent outcome based on the modified Rankin Scale at about 3 months. Safety and functional improvements will also be tracked through clinical evaluations and imaging. The entire participation lasts until the 90-day assessment after treatment.

Age: 18Years +All GendersPhase 3
15 locations